University of Sydney;Mirrx Therapeutics A/S;Centenary Institute of Cancer Medicine and Cell Biology
发明人:
Gamble, Jennifer,Vadas, Mathew,Moller, Thorleif
申请号：
AU2013327393
公开号：
AU2013327393B2
申请日:
2013.10.02
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
The present invention provides oligonucleotides that inhibit the binding of miR-27a to VE-cadherin mRNA, particularly in the form of blockmirs. The invention also provides compositions comprising such oligonucleotides and methods of use of such oligonucleotides to modulate the activity of VE-cadherin, inhibit or reduce vascular permeability, treat or prevent a vascular permeability-associated disease or condition, inhibit tumour growth, treat ischaemic injury, enhance recovery from ischaemic injury, treat surgical wounds and/or promotes post-operative recovery, and promote or induce angiogenesis.
